Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Giroctocogene fitelparvovec - Pfizer/Sangamo

Next Previous
X
Search
Drug Profile

Giroctocogene fitelparvovec - Pfizer/Sangamo

Alternative Names: AAV cDNA gene therapy - Sangamo Therapeutics; AAV cDNA hF8 gene therapy; AAV cDNA human Factor 8 gene therapy; AAV Factor 8 cDNA gene therapy; AAV Factor 8 cDNA in vivo gene therapy; PF 07055480; Recombinant AAV2/6 human Factor 8 gene therapy - Sangamo Therapeutics; Recombinant AAV2/6 human Factor VIII gene therapy - Sangamo Therapeutics; SB-525; SB-525 cDNA gene therapy

Latest Information Update: 10 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sangamo BioSciences
  • Developer Pfizer
  • Class Antihaemorrhagics; Gene therapies
  • Mechanism of Action Factor VIII replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Haemophilia A

Most Recent Events

  • 30 Dec 2024 Pfizer plans to terminate license agreement with Sangamo Therapeutics for Hemophilia A on 21 April 2025
  • 30 Dec 2024 Sangamo Therapeutics announces intention to launch Giroctocogene fitelparvovec for Hemophilia A
  • 30 Dec 2024 Giroctocogene fitelparvovec - Pfizer is available for licensing as of 30 Dec 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top